There is a thought experiment I return to often when thinking about American healthcare. Imagine you own a house. The roof develops a small leak. You could fix it now for $500. Instead, you wait. Rain comes. The leak damages the ceiling. Mold develops in the walls. The ceiling eventually collapses into the living room. Now the repair costs $75,000. Also, you and your family have been breathing mold spores for two years and have developed respiratory problems that will require ongoing medical treatment.
This is not a perfect analogy for the American healthcare system. But it is not a terrible one, either. The United States has constructed, over the course of a century, the most sophisticated acute-care medical system in human history — and paired it with one of the most anemic preventive care systems in the developed world. We are extraordinarily good at intervening after catastrophe and extraordinarily bad at preventing catastrophe from occurring. And the cost of this imbalance, in both dollars and lives, is staggering.
The spending paradox
The United States spends approximately $4.3 trillion annually on healthcare — roughly 18.3% of GDP, more than any other country by a substantial margin (CMS, 2023). The next highest spender, Germany, allocates approximately 12.7%. The OECD average is 9.6%. By any measure, America is not under-investing in health.
But where does that money go? A comprehensive analysis published in JAMA found that approximately 97% of US health expenditures are allocated to treatment of existing diseases, while only 3% — roughly $129 billion — is spent on preventive care and public health (Woolf & Aron, 2013). That 3% encompasses everything from vaccination programs to workplace safety regulations to preventive screenings to public health infrastructure.
To put this in perspective: the United States spends more treating Type 2 diabetes alone ($327 billion annually) than it spends on all preventive care combined (American Diabetes Association, 2018). The Diabetes Prevention Program demonstrated that a modest lifestyle intervention costing approximately $2,650 per person could reduce diabetes incidence by 58% — but fewer than 10% of eligible Americans have access to such programs (Albright & Gregg, 2013). We have the evidence. We have the tools. We have chosen not to deploy them.
The historical roots of the problem
Understanding why American healthcare is structured this way requires understanding its history, which is fundamentally different from the history of healthcare in peer nations.
Most European healthcare systems were built in the aftermath of World War II, when governments were constructing comprehensive social infrastructure from the ground up. These systems were designed around populations — their goal was keeping entire communities healthy, which naturally emphasized prevention. Universal coverage meant that the financial incentive for the system was to minimize the total cost of health across the population, which meant investing heavily in interventions that prevented expensive downstream disease.
The American system evolved differently. It emerged not from government planning but from the employer-sponsored insurance model that developed during World War II, when wage freezes led companies to attract workers with health benefits instead of higher pay. This accident of history created a system organized around individual episodes of illness rather than population health — a system in which healthcare is transactional, episodic, and fundamentally reactive.
The fee-for-service payment model that dominates American medicine reinforces this reactive orientation at every level. Physicians are paid for procedures performed, not for diseases prevented. A primary care physician who spends thirty minutes counseling a patient on diet, exercise, and stress management — interventions that might prevent cardiovascular disease, diabetes, and depression — is reimbursed a fraction of what a cardiologist receives for a thirty-minute catheterization to treat the heart disease that prevention could have avoided. The incentive structure pays for repair, not maintenance.
The pharmaceutical influence
The pharmaceutical industry, which generates approximately $590 billion in annual revenue in the United States alone, has a structural interest in treatment over prevention. Medications that manage chronic diseases — statins, anti-hypertensives, insulin, antidepressants — generate recurring revenue streams measured in decades. A lifestyle intervention that prevents the disease from developing generates no pharmaceutical revenue at all.
This is not a conspiracy theory. It is basic economics. A study published in the BMJ analyzed pharmaceutical industry funding of medical research and found that clinical trials funded by industry were 3.6 times more likely to report positive findings for the sponsored drug than independently funded trials (Lexchin et al., 2003). The research agenda itself is shaped by commercial interests, which systematically direct scientific attention toward pharmacological interventions and away from the lifestyle, environmental, and social determinants of health that drive most chronic disease.
The influence extends to clinical guidelines. An analysis published in JAMA Internal Medicine found that 71% of guideline panel members had financial conflicts of interest with pharmaceutical companies, and that guidelines authored by conflicted panels were more likely to recommend drug therapy as first-line treatment (Neuman et al., 2011). This does not mean that drug recommendations are wrong — many are well-supported by evidence — but it does mean that the clinical decision-making framework is tilted toward treatment and away from prevention in ways that are not always evidence-based.
The screenings that work — and the ones that don't
Preventive care is not a single thing. It encompasses a wide range of interventions — from vaccinations to screenings to behavioral counseling — with wildly varying evidence bases. And one of the obstacles to effective prevention is the tendency to conflate all preventive care as equally valuable, when in reality, the evidence ranges from overwhelming to negative.
The interventions with the strongest evidence include childhood vaccinations, which are among the most cost-effective health interventions in human history. The CDC estimates that the childhood vaccination program prevents 21 million hospitalizations and 732,000 premature deaths per generation at a net savings of $295 billion in direct medical costs (Zhou et al., 2014). Influenza vaccination in high-risk populations, colorectal cancer screening after age 45, cervical cancer screening with HPV testing, hypertension screening, and tobacco cessation counseling all have robust evidence supporting their cost-effectiveness.
But other widely promoted screenings have more ambiguous evidence. Annual physical examinations — the cornerstone of preventive care in the American model — have surprisingly limited evidence of benefit. A Cochrane review of 17 randomized controlled trials involving over 250,000 participants found that general health checks did not reduce all-cause mortality, cardiovascular mortality, or cancer mortality (Krogsbøll et al., 2019). The authors concluded that while individual components of a health check (blood pressure measurement, cholesterol screening) have documented benefit, the bundled annual exam as traditionally practiced does not demonstrably improve health outcomes.
Prostate cancer screening with PSA testing was recommended for decades before a large randomized trial demonstrated that it led to significant overdiagnosis and overtreatment — detecting and treating cancers that would never have caused symptoms or death — with only modest mortality benefit and substantial harms including incontinence and erectile dysfunction from unnecessary surgery (Schröder et al., 2009). The US Preventive Services Task Force has since recommended shared decision-making rather than routine screening.
The lesson is not that prevention doesn't work. The lesson is that prevention works when it is targeted, evidence-based, and proportional to the risk being addressed — and that untargeted, reflexive screening can generate more harm than benefit through false positives, overdiagnosis, and the cascades of anxiety and intervention they trigger.
The social determinants gap
Perhaps the most fundamental failure of the American preventive care model is its almost exclusive focus on individual clinical interventions — screenings, medications, counseling — while ignoring the social and environmental conditions that drive the majority of health outcomes.
A widely cited analysis published in Health Affairs estimated that clinical care accounts for only 10-20% of modifiable health outcomes. The remaining 80-90% is attributable to social and economic factors (40%), health behaviors (30%), and the physical environment (10%) (McGinnis et al., 2002). Housing quality, food access, neighborhood safety, income stability, educational attainment, environmental pollution — these "social determinants of health" are the primary drivers of the chronic diseases that consume most of the healthcare budget.
Yet the healthcare system is almost entirely structured around clinical interventions. A patient with uncontrolled diabetes may receive insulin, glucose monitoring supplies, nutritional counseling, and regular endocrinology appointments — all appropriate clinical care — while living in a food desert where the nearest source of fresh produce is 15 miles away, working two jobs that leave no time for meal preparation or exercise, and experiencing chronic financial stress that elevates cortisol and worsens insulin resistance.
The clinical interventions address symptoms. The social determinants create them. And no amount of clinical preventive care will close the health gap created by structural inequality.
Some health systems are beginning to address this disconnect. Kaiser Permanente has invested over $200 million in affordable housing initiatives, recognizing that housing stability is as relevant to health outcomes as any clinical intervention. Geisinger Health System created the Fresh Food Farmacy, which provides free fresh food prescriptions to patients with diabetes and has demonstrated significant reductions in hemoglobin A1c and healthcare utilization (Feinberg et al., 2018). These are promising models, but they remain exceptions rather than the rule.
The primary care crisis
Even within the clinical domain, the infrastructure required for effective prevention — primary care — is in crisis. The Association of American Medical Colleges projects a shortage of between 17,800 and 48,000 primary care physicians by 2034 (AAMC, 2021). In rural areas, the shortage is already severe, with over 80 million Americans living in federally designated primary care shortage areas.
The pipeline problem is structural. Medical students graduate with an average debt of $203,000. Primary care physicians earn, on average, $260,000 annually — roughly half of what most specialists earn. The financial calculus is straightforward and devastating: students with six-figure debt disproportionately choose higher-paying specialties, depleting the primary care workforce that prevention depends on.
Average panel sizes have increased as the physician workforce has shrunk relative to population: the typical primary care physician now manages 2,300 patients (Altschuler et al., 2012). At 18 minutes per visit and an average of 3.1 complaints per encounter, the time available for preventive counseling, behavioral change support, and chronic disease management is negligible. The system demands volume, not value.
What effective prevention actually looks like
The countries that achieve the best health outcomes with the lowest per-capita spending share several features that are largely absent from the American system:
Universal access. Every developed country that outperforms the United States on standard health metrics provides universal healthcare coverage. This is not coincidental. When care is universally accessible, financial barriers to early intervention are eliminated. Conditions are detected and managed before they become expensive emergencies.
Strong primary care. Countries like Denmark, the Netherlands, and Australia invest heavily in primary care, with robust gatekeeper models that ensure most health needs are addressed in the community rather than in hospitals. Primary care physicians in these systems have smaller panels, longer appointment times, and financial incentives aligned with prevention rather than volume.
Public health infrastructure. European and Asian countries with the best health outcomes invest substantially in public health — clean water, food safety, environmental regulation, workplace safety, health education — as a complement to clinical care. These investments address the upstream determinants of health that clinical care alone cannot modify.
Behavioral support systems. Countries like Finland and Japan integrate behavioral health support into routine care, with systematic programs for smoking cessation, alcohol reduction, physical activity promotion, and dietary improvement that are funded, staffed, and measured as core health system functions rather than afterthoughts.
The path forward
The political and economic obstacles to transforming the American healthcare system's orientation from treatment to prevention are enormous. The treatment industry — hospitals, specialists, pharmaceutical companies, device manufacturers — generates trillions of dollars in annual revenue and employs millions of people. Prevention, by definition, reduces demand for their services. The political economy of American healthcare is structured around illness, and restructuring it around health will require overcoming formidable financial and institutional resistance.
But the case for change is also overwhelming. The current system is unsustainable: healthcare spending is projected to reach 20% of GDP by 2030, driven overwhelmingly by the treatment of preventable chronic diseases. The human toll is equally unsustainable: life expectancy in the United States has declined for three consecutive years — something not seen since before the development of penicillin — while life expectancy in peer nations continues to rise.
The fix is not more spending. We already spend more than anyone. The fix is different spending — upstream, early, structural, and sustained. It is fixing the roof when the leak is small, not rebuilding the house after the ceiling has collapsed.
References
- AAMC. (2021). The Complexities of Physician Supply and Demand. Association of American Medical Colleges.
- Albright, A. L., & Gregg, E. W. (2013). Preventing type 2 diabetes in communities across the US. American Journal of Preventive Medicine, 44(4), S346–S351.
- Altschuler, J., et al. (2012). Estimating a reasonable patient panel size. Annals of Family Medicine, 10(5), 396–400.
- American Diabetes Association. (2018). Economic costs of diabetes in the US in 2017. Diabetes Care, 41(5), 917–928.
- CMS. (2023). National Health Expenditure Data. Centers for Medicare & Medicaid Services.
- Feinberg, A. T., et al. (2018). Prescribing food as a specialty drug. Academic Medicine, 93(2), 185–189.
- Krogsbøll, L. T., et al. (2019). General health checks in adults. Cochrane Database, (1), CD009009.
- Lexchin, J., et al. (2003). Pharmaceutical industry sponsorship and research outcome. BMJ, 326(7400), 1167–1170.
- McGinnis, J. M., et al. (2002). The case for more active policy attention to health promotion. Health Affairs, 21(2), 78–93.
- Neuman, J., et al. (2011). Prevalence of financial conflicts of interest among panel members. JAMA Internal Medicine, 171(6), 620–628.
- Schröder, F. H., et al. (2009). Screening and prostate-cancer mortality in a randomized European study. NEJM, 360(13), 1320–1328.
- Woolf, S. H., & Aron, L. (2013). US Health in International Perspective. National Academies Press.
- Zhou, F., et al. (2014). Economic evaluation of the routine childhood immunization program. Pediatrics, 133(4), 577–585.